Analysis of tamoxifen-DNA adducts in endometrial explants by MS and 32P-postlabeling

Biochemical and Biophysical Research Communications

Volumn 320, Issue 2, 2004, Pages 297-302

  Beland, Frederick A ^a   Churchwell, Mona I ^a   Hewer, Alan ^b   Phillips, David H ^b   Gamboa Da Costa, Gonçalo ^c   Marques, M Matilde ^c  

^a NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c INSTITUTO SUPERIOR TÉCNICO   (Portugal)

Author keywords

32P postlabeling; DNA adducts; Electrospray ionization tandem mass spectrometry; Endometrial cancer; HPLC; Tamoxifen

Indexed keywords

PHOSPHORUS 32; TAMOXIFEN;

ARTICLE; CONTROLLED STUDY; DNA ADDUCT; ELECTROSPRAY MASS SPECTROMETRY; ENDOMETRIUM; EXPLANT; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; NONHUMAN; PRIORITY JOURNAL; RAT;

CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DNA; DNA ADDUCTS; ENDOMETRIUM; FEMALE; HUMANS; PHOSPHORUS RADIOISOTOPES; SPECTROMETRY, FLUORESCENCE; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; TAMOXIFEN;

EID: 2942741026     PISSN: 0006291X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbrc.2004.05.168     Document Type: Article

References (24)

1. Early Breast Cancer Trialists' Collaborative Group, Tamoxifen for early breast cancer: an overview of the randomised trials, Lancet 351 (1998) 1451-1467
2. B. Fisher, J.P. Costantino, D.L. Wickerham, C.K. Redmond, M. Kavanah, W.M. Cronin, V. Vogel, A. Robidoux, N. Dimitrov, J. Atkins, M. Daly, S. Wieand, E. Tan-Chiu, L. Ford, N. Wolmark, and other National Surgical Adjuvant Breast and Bowel Project Investigators, Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study, J. Natl. Cancer Inst. 90 (1998) 1371-1388
3. U. Veronesi, P. Maisonneuve, V. Sacchini, N. Rotmensz, P. Boyle, and the Italian Tamoxifen Study Group, Tamoxifen for breast cancer among hysterectomised women, Lancet 359 (2002) 1122-1124
4. IBIS investigators, First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial, Lancet 360 (2002) 817-824
5. Cuzick J., Powles T., Veronesi U., Forbes J., Edwards R., Ashley S., Boyle P. Overview of the main outcomes in breast-cancer prevention trials. Lancet. 361:2003;296-300
6. Bergh J. Breast-cancer prevention: is the risk-benefit ratio in favour of tamoxifen? Lancet. 362:2003;183-184
7. Phillips D.H. Understanding the genotoxicity of tamoxifen? Carcinogenesis. 22:2001;839-849
8. White I.N.H. Anti-oestrogenic drugs and endometrial cancers. Toxicol. Lett. 120:2001;21-29
9. Hemminki K., Rajaniemi H., Lindahl B., Moberger B. Tamoxifen-induced DNA adducts in endometrial samples from breast cancer patients. Cancer Res. 56:1996;4374-4377
10. Shibutani S., Suzuki N., Terashima I., Sugarman S.M., Grollman A.P., Pearl M.L. Tamoxifen-DNA adducts detected in the endometrium of women treated with tamoxifen. Chem. Res. Toxicol. 12:1999;646-653
11. Shibutani S., Ravindernath A., Suzuki N., Terashima I., Sugarman S.M., Grollman A.P., Pearl M.L. Identification of tamoxifen-DNA adducts in the endometrium of women treated with tamoxifen. Carcinogenesis. 21:2000;1461-1467
12. Martin E.A., Brown K., Gaskell M., Al-Azzawi F., Garner R.C., Boocock D.J., Mattock E., Pring D.W., Dingley K., Turteltaub K.W., Smith L.L., White I.N.H. Tamoxifen DNA damage detected in human endometrium using accelerator mass spectrometry. Cancer Res. 63:2003;8461-8465
13. Carmichael P.L., Ugwumadu A.H.N., Neven P., Hewer A.J., Poon G.K., Phillips D.H. Lack of genotoxicity of tamoxifen in human endometrium. Cancer Res. 56:1996;1475-1479
14. 32P-post-labelling for tamoxifen-DNA adducts in the human endometrium. Carcinogenesis. 20:1999;339-342
15. 32P-postlabeling analyses of tamoxifen-DNA adducts in humans, J. Natl. Cancer Inst. (2004), in press
16. Sharma M., Shubert D.E., Sharma M., Rodabaugh K.J., McGarrigle B.P., Vezina C.M., Bofinger D.P., Olson J.R. Antioxidant inhibits tamoxifen-DNA adducts in endometrial explant culture. Biochem. Biophys. Res. Commun. 307:2003;157-164
17. Poirier M.C., Schild L.J. The genotoxicity of tamoxifen: extent and consequences, Kona, Hawaii, January 23, 2003. Mutagenesis. 18:2003;395-399
18. Gamboa da Costa G., Marques M.M., Beland F.A., Freeman J.P., Churchwell M.I., Doerge D.R. Quantification of tamoxifen DNA adducts using on-line sample preparation and HPLC-electrospray ionization tandem mass spectrometry. Chem. Res. Toxicol. 16:2003;357-366
19. Gamboa da Costa G., McDaniel-Hamilton L.P., Heflich R.H., Marques M.M., Beland F.A. DNA adduct formation and mutant induction in Sprague-Dawley rats treated with tamoxifen and its derivatives. Carcinogenesis. 22:2001;1307-1315
20. Gamboa da Costa G., Hamilton L.P., Beland F.A., Marques M.M. Characterization of the major DNA adduct formed by α-hydroxy-. N -desmethyltamoxifen in vitro and in vivo Chem. Res. Toxicol. 13:2000;200-207
21. Gamboa da Costa G., Marques M.M., Freeman J.P., Beland F.A. Synthesis and investigation of α-hydroxy-. N, N -didesmethyltamoxifen as a proximate carcinogen in the metabolic activation of tamoxifen Chem. Res. Toxicol. 16:2003;1090-1098
22. Phillips D.H., Castegnaro M. On behalf of the trail participants, Standardization and validation of DNA adduct postlabelling methods: report of interlaboratory trials and production of recommended protocols. Mutagenesis. 14:1999;301-315
23. Kim S.Y., Suzuki N., Laximi Y.R.S., Shibutani S. Formation of DNA adducts through O-sulfation, not O-acetylation, of α-hydroxytamoxifen. Proc. Am. Assoc. Cancer Res. 45:2004;532
24. Brown K., Carmichael P.L. Correspondence regarding M. Sharma et al., "Antioxidant inhibits tamoxifen-DNA adducts in endometrial explant culture" Biochem. Biophys. Res. Commun. 310:2003;1039